Sunitinib- or sorafenib-induced VEGFR inhibition reduces the production of the vasorelaxant nitric oxide (NO) by endothelial cells, in turn resulting in hypertension. In turn, hypertension may lead to capillary rarefaction, which may cause LV dysfunction [reviewed in (15, 194)]. Sunitinib- or sorafenib-induced VEGFR inhibition reduces angiogenesis resulting in LV dysfunction [reviewed in (15, 194)]. Sunitinib- or sorafenib-induced PDGFR inhibition induces the loss of pericytes, leading to coronary microvascular dysfunction and LV dysfunction [reviewed in (15, 194)]. Here, PDGFRB is linked to hypertensive disorder.